Expertise in
3
conditions

Jae H. Seo

Seoul, KR 
Expertise in
3
conditions
Seoul, KR 

Overview

Jae Seo practices practicing medicine in Seoul, Republic of Korea.

Seo is highly rated in 3 conditions, according to our data. Their clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, and Febrile Neutropenia.

They are actively involved in clinical research, co-authoring 31 peer reviewed articles and participating in 2 clinical trials.

Locations

Seoul, Republic of Korea
Other Locations
Gyeonggi-do, 420743, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC
A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC
Enrollment Status: Completed
Publish Date: March 05, 2024
Intervention Type: Drug
Study Drugs: GX-I7, Pembrolizumab, cyclophosphamide
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

31 Total Publications

Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.
Ebastine targets HER2/HER3 signaling and cancer stem cell traits to overcome trastuzumab resistance in HER2‑positive breast cancer.
Journal: International journal of molecular medicine
Published: August 11, 2025

Frequently Asked Questions about Jae H. Seo

Is Jae H. Seo a top-rated expert for Triple-Negative Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Jae H. Seo is classified as an Advanced expert for Triple-Negative Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jae H. Seo participate in research or clinical trials?

Yes. Jae H. Seo has published 31 articles and abstracts on conditions like Triple-Negative Breast Cancer. You can view a list of Jae H. Seo's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Seo's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile